Here are the DEF 14A proxy statements from Co-Diagnostics, Inc. (CODX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CODX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CODX filings page.
Co-Diagnostics, Inc. is asking shareholders to vote at a special meeting on November 13, 2026, on nine proposals, including five director nominees, an equity-plan amendment, advisory executive compensation, auditor ratification, a quorum amendment, warrant and convertible-note share issuance, a reverse split authorization and adjournment. A court order sets the quorum for each applicable voting group at one-third of the votes entitled to be cast.
The proposed equity-plan amendment would add 2,000,000 shares to the existing 263,376-share authorization, for 2,263,376 shares if approved. The requested increase represents approximately 22.7% of the 8,822,648 common shares outstanding as of October 22, 2026. Other proposals seek approval of the potential exercise of 3,404,724 warrants at $1.56 per share and the issuance of shares upon conversion of secured convertible notes. Shareholders are also asked to authorize one or more reverse splits at a ratio of not less than 1-for-2, with a cumulative effect not to exceed 1-for-750; the board would determine the ratio and timing within twelve months after the meeting.
Co-Diagnostics, Inc. is calling a shareholders’ meeting on September 3, 2026 in Salt Lake City to vote on six proposals, including electing five directors, an advisory vote on executive pay, ratifying auditor Tanner LLC for 2026, amending quorum rules, and potential adjournment.
A key item seeks to increase the share reserve under the 2025 Equity Incentive Plan by 2,000,000 shares, bringing the plan total to 2,223,333 shares versus 5,278,957 common shares outstanding as of July 7, 2026. The company highlights that this pool could represent up to 42.1% of current outstanding shares, or 20.4% of as-adjusted diluted capitalization when including approximately 3,400,000 warrants at a $1.58 exercise price.
The board (four of five directors are independent) recommends voting “FOR” all proposals. 2025 compensation totaled $528,750 for CEO Dwight Egan, $421,250 for CFO Brian Brown, and $360,000 for President Richard Abbott, with significant RSU grants. A change-in-control severance plan provides cash severance of three times pay-plus-bonus for the CEO and two times for the CFO upon qualifying terminations. Directors and executives as a group beneficially own 2.3% of common stock.